Which has stronger earnings and valuation, OPK or BDSX?

Biodesix has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OPKO Health $606.90M 1.71 -$225.68M -$0.09 N/A Biodesix $88.50M 3.15 -$35.26M -$3.17 N/A

Is OPK or BDSX more profitable?

OPKO Health has a net margin of -12.40% compared to Biodesix's net margin of -26.97%. OPKO Health's return on equity of -5.88% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets OPKO Health -12.40% -5.88% -3.83% Biodesix -26.97% -788.19% -30.33%

Does the media favor OPK or BDSX?

In the previous week, OPKO Health had 5 more articles in the media than Biodesix. MarketBeat recorded 9 mentions for OPKO Health and 4 mentions for Biodesix. OPKO Health's average media sentiment score of 0.75 beat Biodesix's score of 0.26 indicating that OPKO Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biodesix 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BDSX or CSTL?

In the previous week, Castle Biosciences had 10 more articles in the media than Biodesix. MarketBeat recorded 14 mentions for Castle Biosciences and 4 mentions for Biodesix. Castle Biosciences' average media sentiment score of 0.38 beat Biodesix's score of 0.26 indicating that Castle Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Castle Biosciences 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BDSX or LMRI?

In the previous week, Lumexa Imaging had 2 more articles in the media than Biodesix. MarketBeat recorded 6 mentions for Lumexa Imaging and 4 mentions for Biodesix. Biodesix's average media sentiment score of 0.26 beat Lumexa Imaging's score of 0.17 indicating that Biodesix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lumexa Imaging 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is FLGT or BDSX more profitable?

Fulgent Genetics has a net margin of -26.05% compared to Biodesix's net margin of -26.97%. Fulgent Genetics' return on equity of -4.93% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Fulgent Genetics -26.05% -4.93% -4.50% Biodesix -26.97% -788.19% -30.33%

Does the media favor FLGT or BDSX?

In the previous week, Biodesix had 1 more articles in the media than Fulgent Genetics. MarketBeat recorded 4 mentions for Biodesix and 3 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 0.51 beat Biodesix's score of 0.26 indicating that Fulgent Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Biodesix 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, BDSX or SBC?

SBC Medical Group has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodesix $88.50M 3.15 -$35.26M -$3.17 N/A SBC Medical Group $173.61M 3.16 $50.99M $0.47 11.36

Is BDSX or SBC more profitable?

SBC Medical Group has a net margin of 27.99% compared to Biodesix's net margin of -26.97%. SBC Medical Group's return on equity of 18.47% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -26.97% -788.19% -30.33% SBC Medical Group 27.99% 18.47% 13.10%

Does the media refer more to BDSX or SBC?

In the previous week, Biodesix had 1 more articles in the media than SBC Medical Group. MarketBeat recorded 4 mentions for Biodesix and 3 mentions for SBC Medical Group. SBC Medical Group's average media sentiment score of 0.54 beat Biodesix's score of 0.26 indicating that SBC Medical Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SBC Medical Group 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Biodesix (BDSX) Competitors

$25.63 -0.79 (-2.99%)

Closing price 04:00 PM Eastern

Extended Trading

$25.66 +0.03 (+0.10%)

As of 04:15 PM Eastern

Compare

BDSX vs. OPK, CSTL, LMRI, FLGT, and SBC

Should you buy Biodesix stock or one of its competitors? Biodesix's main competitors and comparable companies include OPKO Health (OPK), Castle Biosciences (CSTL), Lumexa Imaging (LMRI), Fulgent Genetics (FLGT), and SBC Medical Group (SBC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Biodesix compare to OPKO Health?

OPKO Health (NASDAQ:OPK) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

OPKO Health has a net margin of -12.40% compared to Biodesix's net margin of -26.97%. OPKO Health's return on equity of -5.88% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-12.40%	-5.88%	-3.83%
Biodesix	-26.97%	-788.19%	-30.33%

OPKO Health has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

64.6% of OPKO Health shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 44.7% of OPKO Health shares are held by company insiders. Comparatively, 23.2% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

OPKO Health presently has a consensus target price of $1.55, indicating a potential upside of 11.51%. Biodesix has a consensus target price of $35.00, indicating a potential upside of 32.48%. Given Biodesix's stronger consensus rating and higher probable upside, analysts plainly believe Biodesix is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Biodesix has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.71	-$225.68M	-$0.09	N/A
Biodesix	$88.50M	3.15	-$35.26M	-$3.17	N/A

In the previous week, OPKO Health had 5 more articles in the media than Biodesix. MarketBeat recorded 9 mentions for OPKO Health and 4 mentions for Biodesix. OPKO Health's average media sentiment score of 0.75 beat Biodesix's score of 0.26 indicating that OPKO Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biodesix	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

OPKO Health beats Biodesix on 10 of the 16 factors compared between the two stocks.

How does Biodesix compare to Castle Biosciences?

Biodesix (NASDAQ:BDSX) and Castle Biosciences (NASDAQ:CSTL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Biodesix has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Castle Biosciences has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

Castle Biosciences has a net margin of -5.43% compared to Biodesix's net margin of -26.97%. Castle Biosciences' return on equity of -4.15% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-26.97%	-788.19%	-30.33%
Castle Biosciences	-5.43%	-4.15%	-3.45%

Biodesix currently has a consensus price target of $35.00, suggesting a potential upside of 32.48%. Castle Biosciences has a consensus price target of $42.00, suggesting a potential upside of 27.27%. Given Biodesix's higher probable upside, research analysts plainly believe Biodesix is more favorable than Castle Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Castle Biosciences has higher revenue and earnings than Biodesix. Castle Biosciences is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	3.15	-$35.26M	-$3.17	N/A
Castle Biosciences	$344.23M	2.93	-$24.16M	-$0.66	N/A

21.0% of Biodesix shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 23.2% of Biodesix shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Castle Biosciences had 10 more articles in the media than Biodesix. MarketBeat recorded 14 mentions for Castle Biosciences and 4 mentions for Biodesix. Castle Biosciences' average media sentiment score of 0.38 beat Biodesix's score of 0.26 indicating that Castle Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Castle Biosciences	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Castle Biosciences beats Biodesix on 11 of the 15 factors compared between the two stocks.

How does Biodesix compare to Lumexa Imaging?

Biodesix (NASDAQ:BDSX) and Lumexa Imaging (NASDAQ:LMRI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

In the previous week, Lumexa Imaging had 2 more articles in the media than Biodesix. MarketBeat recorded 6 mentions for Lumexa Imaging and 4 mentions for Biodesix. Biodesix's average media sentiment score of 0.26 beat Lumexa Imaging's score of 0.17 indicating that Biodesix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lumexa Imaging	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

21.0% of Biodesix shares are owned by institutional investors. 23.2% of Biodesix shares are owned by company insiders. Comparatively, 0.7% of Lumexa Imaging shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lumexa Imaging has a net margin of 0.00% compared to Biodesix's net margin of -26.97%. Lumexa Imaging's return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-26.97%	-788.19%	-30.33%
Lumexa Imaging	N/A	N/A	N/A

Biodesix presently has a consensus price target of $35.00, indicating a potential upside of 32.48%. Lumexa Imaging has a consensus price target of $16.40, indicating a potential upside of 54.86%. Given Lumexa Imaging's stronger consensus rating and higher probable upside, analysts clearly believe Lumexa Imaging is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

Biodesix has higher earnings, but lower revenue than Lumexa Imaging. Lumexa Imaging is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	3.15	-$35.26M	-$3.17	N/A
Lumexa Imaging	$267.73M	3.80	-$47.10M	-$0.49	N/A

Summary

Lumexa Imaging beats Biodesix on 10 of the 15 factors compared between the two stocks.

How does Biodesix compare to Fulgent Genetics?

Fulgent Genetics (NASDAQ:FLGT) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Fulgent Genetics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

48.1% of Fulgent Genetics shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 36.2% of Fulgent Genetics shares are held by company insiders. Comparatively, 23.2% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Biodesix has lower revenue, but higher earnings than Fulgent Genetics. Biodesix is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.75	-$60.51M	-$2.82	N/A
Biodesix	$88.50M	3.15	-$35.26M	-$3.17	N/A

In the previous week, Biodesix had 1 more articles in the media than Fulgent Genetics. MarketBeat recorded 4 mentions for Biodesix and 3 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 0.51 beat Biodesix's score of 0.26 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Biodesix	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fulgent Genetics presently has a consensus target price of $27.50, indicating a potential upside of 33.69%. Biodesix has a consensus target price of $35.00, indicating a potential upside of 32.48%. Given Fulgent Genetics' higher probable upside, research analysts plainly believe Fulgent Genetics is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Fulgent Genetics has a net margin of -26.05% compared to Biodesix's net margin of -26.97%. Fulgent Genetics' return on equity of -4.93% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
Biodesix	-26.97%	-788.19%	-30.33%

Summary

Fulgent Genetics beats Biodesix on 11 of the 17 factors compared between the two stocks.

How does Biodesix compare to SBC Medical Group?

Biodesix (NASDAQ:BDSX) and SBC Medical Group (NASDAQ:SBC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Biodesix currently has a consensus price target of $35.00, suggesting a potential upside of 32.48%. SBC Medical Group has a consensus price target of $8.50, suggesting a potential upside of 59.18%. Given SBC Medical Group's higher probable upside, analysts clearly believe SBC Medical Group is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
SBC Medical Group	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Biodesix had 1 more articles in the media than SBC Medical Group. MarketBeat recorded 4 mentions for Biodesix and 3 mentions for SBC Medical Group. SBC Medical Group's average media sentiment score of 0.54 beat Biodesix's score of 0.26 indicating that SBC Medical Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SBC Medical Group	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SBC Medical Group has a net margin of 27.99% compared to Biodesix's net margin of -26.97%. SBC Medical Group's return on equity of 18.47% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-26.97%	-788.19%	-30.33%
SBC Medical Group	27.99%	18.47%	13.10%

21.0% of Biodesix shares are owned by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are owned by institutional investors. 23.2% of Biodesix shares are owned by company insiders. Comparatively, 81.7% of SBC Medical Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

SBC Medical Group has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	3.15	-$35.26M	-$3.17	N/A
SBC Medical Group	$173.61M	3.16	$50.99M	$0.47	11.36

Biodesix has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Summary

SBC Medical Group beats Biodesix on 12 of the 16 factors compared between the two stocks.

Get Biodesix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDSX vs. The Competition

Export

Metric	Biodesix	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$270.40M	$9.80B	$7.14B	$13.21B
Dividend Yield	N/A	2.61%	2.53%	16.47%
P/E Ratio	-8.09	33.82	275.15	25.94
Price / Sales	3.06	4.79	566.78	83.59
Price / Cash	N/A	119.03	77.41	52.81
Price / Book	-82.68	5.09	10.80	6.27
Net Income	-$35.26M	$315.68M	$3.50B	$382.13M
7 Day Performance	-6.22%	-0.79%	-2.02%	-1.39%
1 Month Performance	-3.76%	-3.25%	-7.54%	-5.62%
1 Year Performance	230.71%	8.48%	3.31%	-1.54%

Biodesix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDSX Biodesix	4.1517 of 5 stars	$25.63 -3.0%	$35.00 +36.6%	+261.9%	$270.40M	$88.50M	N/A	334
OPK OPKO Health	1.6511 of 5 stars	$1.54 -2.2%	$1.55 +1.0%	-9.7%	$1.15B	$606.90M	N/A	1,373	News Coverage
CSTL Castle Biosciences	2.8469 of 5 stars	$34.06 -7.1%	$42.00 +23.3%	+44.0%	$1.05B	$357.28M	N/A	1,002	Insider Trade
LMRI Lumexa Imaging	4.1868 of 5 stars	$10.65 -1.2%	$16.40 +54.1%	N/A	$1.02B	$267.73M	N/A	5,019	Analyst Forecast
FLGT Fulgent Genetics	2.9715 of 5 stars	$20.89 -7.0%	$27.50 +31.7%	-9.1%	$574.33M	$322.67M	N/A	1,315

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDSX) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biodesix (BDSX) Competitors

BDSX vs. OPK, CSTL, LMRI, FLGT, and SBC

How does Biodesix compare to OPKO Health?

Summary

How does Biodesix compare to Castle Biosciences?

Summary

How does Biodesix compare to Lumexa Imaging?

Summary

How does Biodesix compare to Fulgent Genetics?

Summary

How does Biodesix compare to SBC Medical Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDSX vs. The Competition

Biodesix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biodesix (BDSX) Competitors

BDSX vs. OPK, CSTL, LMRI, FLGT, and SBC

How does Biodesix compare to OPKO Health?

Is OPK or BDSX more profitable?

Which has more risk & volatility, OPK or BDSX?

Do institutionals and insiders have more ownership in OPK or BDSX?

Do analysts rate OPK or BDSX?

Which has stronger earnings and valuation, OPK or BDSX?

Does the media favor OPK or BDSX?

Summary

How does Biodesix compare to Castle Biosciences?

Which has more risk & volatility, BDSX or CSTL?

Is BDSX or CSTL more profitable?

Do analysts prefer BDSX or CSTL?

Which has higher earnings & valuation, BDSX or CSTL?

Do institutionals & insiders hold more shares of BDSX or CSTL?

Does the media refer more to BDSX or CSTL?

Summary

How does Biodesix compare to Lumexa Imaging?

Does the media favor BDSX or LMRI?

Do insiders and institutionals have more ownership in BDSX or LMRI?

Is BDSX or LMRI more profitable?

Do analysts prefer BDSX or LMRI?

Which has stronger earnings & valuation, BDSX or LMRI?

Summary

How does Biodesix compare to Fulgent Genetics?

Which has more risk & volatility, FLGT or BDSX?

Do insiders & institutionals believe in FLGT or BDSX?

Which has preferable earnings & valuation, FLGT or BDSX?

Does the media favor FLGT or BDSX?

Do analysts prefer FLGT or BDSX?

Is FLGT or BDSX more profitable?

Summary

How does Biodesix compare to SBC Medical Group?

Do analysts recommend BDSX or SBC?

Does the media refer more to BDSX or SBC?

Is BDSX or SBC more profitable?

Do insiders and institutionals hold more shares of BDSX or SBC?

Which has higher earnings and valuation, BDSX or SBC?

Which has more risk & volatility, BDSX or SBC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDSX vs. The Competition

Biodesix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools